Form 4: Nuvation Bio VP Finance Granted Significant Equity Awards

Nuvation Bio Inc.'s VP of Finance, Moses Makunje, was granted 50,761 Restricted Stock Units and options to purchase 224,439 shares of Class A Common Stock.

Summary

• Moses Makunje, VP, Finance and principal financial and accounting officer of Nuvation Bio Inc. (NUVB), reported new equity grants.
• On February 27, 2026, Makunje was granted 50,761 Restricted Stock Units (RSUs) of Class A Common Stock.
• These RSUs will vest 25% annually over four years, contingent on continuous service.
• Makunje also received options to purchase 224,439 shares of Class A Common Stock with an exercise price of $5.91.
• These options will vest 25% on the one-year anniversary of February 27, 2026, and then monthly over the subsequent 36 months, also subject to continuous service.
• Following these transactions, Makunje beneficially owns 68,137 shares of Class A Common Stock and 224,439 stock options.
• The reported beneficial ownership of common stock includes 1,001 shares acquired on May 19, 2025, and 1,100 shares acquired on November 19, 2025, through the 2021 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term company performance and retention. It's not a significant catalyst but indicates ongoing executive commitment.

Positives

• Grant of 50,761 Restricted Stock Units (RSUs) to a key executive, aligning management's interests with shareholder value.
• Grant of options to purchase 224,439 shares, providing long-term incentive for the VP of Finance.
• The vesting schedules for both RSUs and options encourage continuous service and long-term commitment from a principal financial officer.

Negatives

• No immediate cash proceeds for the executive from these grants, as they are vesting awards.
• Potential future dilution for existing shareholders upon the vesting and exercise of these equity awards.

Risks

• The vesting of RSUs and options is contingent on the reporting person's continuous service, meaning forfeiture if employment ceases before vesting.
• The value of the stock options is dependent on the future market price of Nuvation Bio Inc.'s Class A Common Stock exceeding the $5.91 exercise price.

Future Outlook

The filing details future vesting schedules for equity awards, indicating a long-term incentive structure for the executive through February 2030 for RSUs and February 2029 for options (based on 4-year vesting).

Management Comments

• Title: VP, Finance and principal financial and accounting officer.

Industry Context

StockSavvy.ai notes that equity grants, including RSUs and stock options, are standard compensation practices in the biotechnology and pharmaceutical industries, particularly for key executives. These grants are designed to align executive incentives with long-term shareholder value creation and retention, which is crucial in R&D-intensive sectors like Nuvation Bio's.

Comparison to Industry Standards

• Equity grants of this magnitude for a VP of Finance are generally consistent with compensation packages observed in similar-sized biotech companies, especially those in development phases where long-term value creation is paramount.
• The specific number of shares and options would need to be benchmarked against Nuvation Bio's market capitalization and peer group compensation data for a more precise comparison, but the structure is typical.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting and exercise of equity awards, but also potential benefit from aligned executive incentives.
• Employees: Reflects standard executive compensation practices, which can set a precedent or expectation for other employees' long-term incentive plans.
• Management: Provides significant long-term incentive and compensation for the VP of Finance, encouraging retention and performance.

Next Steps

• Continued service by Moses Makunje to ensure vesting of RSUs and stock options.
• Future quarterly vesting dates for RSUs following the first four anniversaries from February 27, 2026.
• Future monthly vesting of stock options over 36 months following the one-year anniversary of February 27, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants. While these grants align management's interests with long-term shareholder value, they do not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. It's a standard disclosure of an expected compensation event.

Keywords

Nuvation Bio, NUVB, Form 4, insider transaction, equity grant, Restricted Stock Units, RSUs, stock options, executive compensation, Moses Makunje, VP Finance, beneficial ownership